COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran
Seyed Massood Nabavi,
Mehrnoosh Mehrabani,
Leila Ghalichi,
Mohammad Ali Nahayati,
Mehran Ghaffari,
Fereshteh Ashtari,
Seyed Ehsan Mohammadianinejad,
Shahedeh Karimi,
Leila Faghani,
Sepideh Yazdanbakhsh,
Abbas Najafian,
Koorosh Shahpasand,
Massoud Vosough
Affiliations
Seyed Massood Nabavi
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Mehrnoosh Mehrabani
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Leila Ghalichi
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Mohammad Ali Nahayati
Neurology Department, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran
Mehran Ghaffari
Neurology Department, Shahid Beheshti University of Medical Sciences, Tehran 1983969411, Iran
Fereshteh Ashtari
Neurology Department, Isfahan University of Medical Sciences, Isfahan 73461-81746, Iran
Seyed Ehsan Mohammadianinejad
Neurology Department, Jondishapour University of Medical Sciences, Ahvaz 15794-61357, Iran
Shahedeh Karimi
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Leila Faghani
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Sepideh Yazdanbakhsh
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Abbas Najafian
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Koorosh Shahpasand
Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran 1665659911, Iran
Massoud Vosough
Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran
Multiple sclerosis (MS) is a chronic, predominantly immune-mediated degenerative disease of the central nervous system. Due to prolonged use of immunomodulatory and immunosuppressive medications, vaccine hesitancy could be common among MS patients. Our main aim in the current study was to evaluate the willingness and acceptability of COVID-19 vaccination in patients with MS. In our multicenter cross-sectional questionnaire-based clinical study, 892 patients completed the questionnaire between May to June 2021. The questionnaire consisted of demographic data, MS disease-related factors, history of COVID-19 infection/vaccination, and any existing comorbidities. Statistical analysis was performed using SPSS software version 19. Overall, 68% of the participants expressed willingness to be vaccinated. Major causes of vaccine refusal in our patients were the fear of reducing the efficacy of disease modifying drugs (DMDs) upon vaccination as well as distrusting the vaccines and overestimation bias in the power of their innate immunity and potential COVID-19 resistance. Some demographic factors affected vaccination enthusiasm in our study. Our findings did not show significant correlation between the age and comorbidity and vaccine willingness. Only one-third of our patients received their vaccine information from healthcare providers. The majority of them received these data from official broadcasting channels and social media. However, despite several concerns, the willingness of COVD-19 vaccination in the Iranian MS patients is remarkable.